Skip to content

Effect of Bushen Huoxue Recipe on coagulation function of polycystic ovary syndrome with kidney deficiency and blood stasis syndrome based on lncrna malat1 regulating p38 MAPK signal pathway

Effect of Bushen Huoxue Recipe on coagulation function of polycystic ovary syndrome with kidney deficiency and blood stasis syndrome based on lncrna malat1 regulating p38 MAPK signal pathway

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037881
Enrollment
Unknown
Registered
2020-09-03
Start date
2020-08-31
Completion date
Unknown
Last updated
2020-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome

Interventions

trial group:Bushen Huoxue Recipe

Sponsors

Fujian Maternity and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of Western medicine and traditional Chinese medicine; 2. Patients aged between 20 and 40 years old; 3. Patients who voluntarily sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Excluding patients with hyperandrogenemia caused by other reasons, such as Cushing syndrome, delayed congenital adrenal hyperplasia, androgen secreting ovarian and adrenal tumors, and other diseases leading to ovulation dysfunction, such as pituitary or hypothalamic amenorrhea, hyperprolactinemia, premature ovarian failure, etc. 2. Patients with organic diseases or other endocrine diseases were excluded; 3. Patients with severe liver and kidney, cardiovascular and cerebrovascular diseases, hematopoietic system dysfunction and psychosis; 4. Patients who have taken hormone and anticoagulant drugs in the past 3 months or participated in other clinical trials; 5. Patients under 20 years old or over 40 years old; 6. Patients who do not meet the inclusion criteria or incomplete data affect the judgment; 7. Patients who can't adhere to the course of treatment, drop out or lose the follow-up; 8. Patients with severe complications in the trial.

Design outcomes

Primary

MeasureTime frame
TCM symptom score;pregnancy outcome;Coagulation related indicators;Gene transcription level of lncRNA-MALAT1, p38MAPK, TXB2;Expression and phosphorylation of p38 signaling pathway related proteins;

Countries

China

Contacts

Public ContactXu Jinbang

Fujian Maternity and Child Health Hospital

jinbangxu@yahoo.com+86 13559958096

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026